Quantifying cutaneous adverse effects of systemic glucocorticoids in patients with rheumatoid arthritis: a cross-sectional cohort study

• Published in: Clinical and experimental rheumatology 2017-05, Vol.35 (3), p.471-476
• Main Authors: Amann, Jonna, Wessels, Anne-Marie, Breitenfeldt, Friederike, Huscher, Dörte, Bijlsma, Johannes W J, Jacobs, Johannes W G, Buttgereit, Frank
• Format: Article
• Language: English
• Subjects: Aged; Arthritis, Rheumatoid - diagnosis; Arthritis, Rheumatoid - drug therapy; Atrophy; Contusions - chemically induced; Contusions - epidemiology; Cross-Sectional Studies; Cushing Syndrome - chemically induced; Cushing Syndrome - epidemiology; Dose-Response Relationship, Drug; Ecchymosis - chemically induced; Ecchymosis - epidemiology; Female; Germany - epidemiology; Glucocorticoids - administration & dosage; Glucocorticoids - adverse effects; Humans; Male; Middle Aged; Prevalence; Risk Assessment; Risk Factors; Self-Assessment; Skin - drug effects; Skin - pathology; Skin Diseases - chemically induced; Skin Diseases - diagnosis; Skin Diseases - epidemiology; Time Factors; Treatment Outcome; Wound Healing - drug effects
• ISSN: 0392-856X

EULAR guidelines state that adverse effects (AEs) of glucocorticoid (GC) therapy should be considered and discussed with the patient before treatment is initiated. However, reliable quantitative data, especially on cutaneous AEs of low-to-medium dose GCs are lacking. We performed a study assessing the occurrence of cutaneous AEs of GCs and its association with current and cumulative GC doses in patients with rheumatoid arthritis (RA). In a cross-sectional study performed in 2 outpatient rheumatology centres, 381 RA patients were enrolled. They were classed into 4 groups, according their mean daily dose during the past 12 months: 0 mg (n=87), 7.5 mg (n=56) of prednisone equivalent. AEs of GC on the skin were assessed by physical examination using a predefined scoring system, and by patients' self-assessments. Data were analysed according GC dose categories and cumulative doses. Cushingoid habitus, easy bruising, skin atrophy, and impaired wound healing as reported by patients occurred significantly more frequently in those using a GC the past 12 months, compared to those not using a GC. At physicians' assessments, only Cushingoid habitus and ecchymosis were more prevalent in GC users. The prevalence of these AEs was statistically significantly positively associated with current and cumulative GC dose. There was low occurrence of abnormal stretch marks, acne, perioral dermatitis, alopecia and hirsutism, which were not correlated with GC use. Certain GC-associated cutaneous AEs are common in RA, but other AEs of GC occur infrequently at the low-to-medium GC doses used in RA.